The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RNAC | -58.97% | -84.13% | -30.79% | -76% |
| S&P | +12.28% | +84.74% | +13.06% | +47% |
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides RNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Gaithersburg, MD.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.45M | 16.8% |
| Gross Profit | $0.45M | 347.5% |
| Gross Margin | 100.00% | 73.9% |
| Market Cap | $265.74M | -22.9% |
| Market Cap / Employee | $6.99M | 0.0% |
| Employees | 38 | 0.0% |
| Net Income | -$35.90M | -48.5% |
| EBITDA | -$21.22M | -246.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $143.38M | -34.6% |
| Accounts Receivable | $0.72M | -87.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.73M | -26.5% |
| Short Term Debt | $3.88M | 39.9% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -102.11% | 0.0% |
| Return On Invested Capital | -407.41% | -225.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.12M | -25.5% |
| Operating Free Cash Flow | -$17.52M | -21.3% |
| Metric | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.83 | 418.81 | -12.37 | -105.15 | 8144.21% |
| Price to Sales | 4.12 | 4.08 | 8.88 | 7.22 | - |
| Price to Tangible Book Value | -0.96 | -1.59 | -1.22 | -1.32 | 179.62% |
| Enterprise Value to EBITDA | 9.79 | -10.11 | -6.16 | -6.36 | -79.96% |
| Return on Equity | -938.4% | - | |||
| Total Debt | $14.65M | $14.07M | $13.35M | $12.60M | -15.23% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
